Apex Capital Management’s Core Laboratories CLB Stock Holding History

Apex Capital Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$26.7M	Buy	237,242 +6,351	+3%	+$660K	0.59%	65
2015 Q4	$25.1M	Sell	230,891 -3,654	-2%	-$418K	0.56%	65
2015 Q3	$23.4M	Buy	234,545 +9,138	+4%	+$994K	0.53%	68
2015 Q2	$25.7M	Buy	225,407 +8,084	+4%	+$980K	0.55%	68
2015 Q1	$22.7M	Buy	217,323 +19,083	+10%	+$2.03M	0.53%	67
2014 Q4	$23.9M	Buy	198,240 +1,875	+1%	+$246K	0.64%	62
2014 Q3	$28.7M	Buy	196,365 +15,265	+8%	+$2.36M	0.87%	50
2014 Q2	$30.3M	Buy	+181,100	New	+$32.2M	0.93%	50

Other funds holding CLB

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Apex Capital Management's CLB Position: Q1 2016 in Review

Apex Capital Management increased its Core Laboratories (CLB) stake by 2.8% in Q1 2016, buying an estimated $660K and bringing the position to 237,242 shares worth $26.7M. The position accounts for 0.59% of the portfolio, ranked #65.

Apex Capital Management first reported a position in CLB in Q2 2014 and has held it in 8 quarters since. The position peaked at $30.3M in Q2 2014. 365 funds tracked by Wall St. Rank hold CLB as of Q1 2016.

Apex Capital Management held 237,242 shares of Core Laboratories worth $26.7M as of Q1 2016.
Apex Capital Management bought 6,351 Core Laboratories shares in Q1 2016, an estimated $660K.
Core Laboratories made up 0.59% of Apex Capital Management's portfolio in Q1 2016, its #65 holding.
Apex Capital Management first reported a position in Core Laboratories in Q2 2014 and has held it in 8 quarters since.
Apex Capital Management's Core Laboratories position peaked at $30.3M in Q2 2014.
365 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.